Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Pfizer's Rare Disease Candidate Meets Endpoint In Phase III

Published 04/01/2018, 09:37 PM
Updated 07/09/2023, 06:31 AM

Pfizer Inc. (NYSE:PFE) announced that a phase III study evaluating its pipeline candidate tafamidis for the treatment of transthyretin cardiomyopathy (TTR-CM) met its primary endpoint.

Top line data from the ATTR-ACT study showed that treatment with tafamidis led to a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations – the primary endpoint - compared with the placebo at 30 months. The safety data also demonstrated that tafamidis was generally well tolerated by patients.

After Pfizer revealed strong late-stage results from the tafamidis study, shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) declined more than 8% and 4%, respectively, on Friday. Both these biotechs have made competing drugs to tafamidis.

TTR-CM is a rare disease associated with progressive heart failure and is universally fatal. Presently, no treatment is approved to treat this fatal disease. According to Pfizer’s press release, less than 1% of people with the disease are diagnosed with life expectancy averaging three to five years from diagnosis.

There are two types of TTR-CM, a hereditary form and a wild-type form of the disease, which is not hereditary. The ATTR-ACT study included both types of patients. However, Alnylam and Ionis have developed their candidates, patisiran and inotersen, respectively, for hereditary TTR amyloidosis, or hATTR. Both patisiran and inotersen are under review in the EU and United States and could be launched this year.

Tafamidis has been granted fast track status by FDA for TTR-CM. Meanwhile, tafamidis also enjoys orphan drug designation for TTR-CM in both the EU and United States.

Tafamidis is already approved for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in 40 countries except United States. In the United States, Pfizer received a complete response letter (CRL) from the FDA on for TTR-FAP in 2012.

Shares of Pfizer have declined 1.1% so far this year, comparing favorably with a 2.7% decrease for the industry.

Zacks Rank & Key Pick

Pfizer carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Another top-ranked large-cap pharma stock is H. Lundbeck (OTC:HLUYY) with the same Zacks Rank as Pfizer.

Shares of H. Lundbeck have returned 12.9% this year so far. Estimates for 2018 increased 8.5% over the past 60 days.

Can Hackers Put Money INTO Your Portfolio?

Earlier this month, credit bureau Equifax (NYSE:EFX) announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.

Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.

Download the new report now>>



Pfizer Inc. (PFE): Free Stock Analysis Report

H Lundbeck A/S (HLUYY): Free Stock Analysis Report

Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report

Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.